FDA D.I.S.C.O. Burst Edition: FDA approv...

Listen to a soundcast of the March 3, 2023, FDA approval of Verzenio (abemaciclib) with endocrine therapy for patients with HR-positive, HER2-negative, node-positive, early breast cancer. 

Listen to a soundcast of the February 9, 2023, FDA approval of Jemperli (dostarlimab-gxly) for mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer that has progressed on or following a prior platinum-containing regimen. 

Listen to a soundcast of the February 3, 2023, FDA approval of Trodelvy (sacituzumab govitecan-hziy) for HR-positive breast cancer. 

In this episode, Michael and Josh take a dive into the world of driver mutations, looking at two of the most clinically consequential: EGFR and ALK mutations. The work done in these areas has led to treatments that represent incredible advances over chemotherapy. How incredible? ... Show More

<p class="" data-rte-preserve-empty="true" style="white-space:pre-wrap;"><strong>This week, we continue talking about relapsed/refractory follicular lymphoma, this time focusing on cellular therapy options, namely bispecific agents and CAR T therapy. If you have not done so, we h ... Show More

In this episode Dr. Timothy Cripe and Dr. Brenda Weigel are joined by FDA's Dr. Nicole Drezner, pediatric oncologist and the Deputy Division Director of the Division of Oncology 2 who led the FDA review and publication on the approval of DFMO. Listen in on the discussion surround ... Show More

This episode examines CAR T-cell therapy’s early successes, broader promise, and emerging risks, as the FDA considers reports of occasional secondary cancers. A full transcript of this episode is available at nejm.org/doi/full/10.1056/NEJMp2400701. 

In our previous episode, we covered the revised FIGO ovarian cancer staging which now includes fallopian tube and peritoneal malignancies. In this episode, we will cover the FIGO guidelines regarding the management of OVFTP cancer. What role do PARP inhibitors play? Does treatmen ... Show More

New FDA-approved therapies for BCG-refractory non-muscle invasive bladder cancer (NMIBC)–where do they fit in the treatment algorithm, and how do you administer them? This installment of the 2025 NMIBC Creator Weekend™ series features host Dr. Bogdana Schmidt, assistant professor ... Show More

In this debut episode of The ASCO Post Podcast, experts in breast, prostate, and lung cancers and multiple myeloma provide clinical insights about selected studies presented at the recent ASCO Annual Meeting, plus news from the FDA.To learn more, visit ascopost.com/podcasts."}" d ... Show More

This is the second of three episodes covering cervical cancer. In this episode, we define locally advanced, metastatic, and recurrent cervical cancer. We will discuss the standard treatment options, including chemotherapy and immunotherapy choices. Join us for bi-weekly episodes ... Show More

Did you know that HER2-targeted therapy is an established treatment option for patients with HER2-positive metastatic gastric/gastroesophageal junction (GEJ) cancer? Credit available for this activity expires: 4/16/25 Earn Credit / Learning Objectives & Disclosures: https://www.m ... Show More